OTCMKTS:IPHYF - Innate Pharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.5450 -0.15 (-2.17 %)
(As of 04/19/2019 04:42 AM ET)
Previous Close$6.69
Today's Range$6.5450 - $6.5450
52-Week Range$5.07 - $10.40
Volume200 shs
Average Volume1,979 shs
Market Capitalization$376.99 million
P/E Ratio109.08
Dividend YieldN/A
Beta0.22
Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. It offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase I clinical trial for cutaneous T-cell lymphomas; Monalizumab, a checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications, as well as in Phase I/II clinical trial for the treatment of solid tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils. The company also provides Lirilumab (IPH2102/BMS-986015), a human monoclonal antibody that blocks the interaction between KIR2DL-1,-2,-3 inhibitory receptors and their ligands; IPH52, an anti-CD39 antibody for immuno-oncology; IPH53, an anti-CD73 antibody for immuno-oncology; and IPH4301, an anti-MICA/B therapeutic antibody to treat oncology. In addition, it offers a commercial-stage product, Lumoxiti, an oncology product for treating hairy cell leukemia. The company has licensing agreements with AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi. Innate Pharma S.A. has a clinical trial collaboration with MedImmune. The company was founded in 1999 and is based in Marseille, France.

Receive IPHYF News and Ratings via Email

Sign-up to receive the latest news and ratings for IPHYF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:IPHYF
Previous SymbolNASDAQ:IPHYF
CUSIPN/A
CIKN/A
Phone33-04-30-30-30-30

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$110.96 million
Cash Flow$0.2096 per share
Book Value$1.80 per share

Profitability

Miscellaneous

Employees195
Market Cap$376.99 million
Next Earnings Date6/19/2019 (Estimated)
OptionableNot Optionable

Innate Pharma (OTCMKTS:IPHYF) Frequently Asked Questions

What is Innate Pharma's stock symbol?

Innate Pharma trades on the OTCMKTS under the ticker symbol "IPHYF."

When is Innate Pharma's next earnings date?

Innate Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, June 19th 2019. View Earnings Estimates for Innate Pharma.

What is the consensus analysts' recommendation for Innate Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innate Pharma.

Has Innate Pharma been receiving favorable news coverage?

Media coverage about IPHYF stock has been trending somewhat positive this week, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Innate Pharma earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the stock's share price in the next few days.

Who are some of Innate Pharma's key competitors?

What other stocks do shareholders of Innate Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innate Pharma investors own include ADOCIA/S (ADOCY), Cellectis (CLLS), Allena Pharmaceuticals (ALNA), InVitae (NVTA), Gulfport Energy (GPOR), GTX (GTXI), Micron Technology (MU), Obseva (OBSV), REDHILL BIOPHAR/S (RDHL) and ZEALAND PHARMA/S (ZEAL).

Who are Innate Pharma's key executives?

Innate Pharma's management team includes the folowing people:
  • Dr. Hervé Brailly, Co-Founder & Chairman of Supervisory Board (Age 58)
  • Dr. Mondher Mahjoubi, Chairman of Exec. Board & CEO (Age 61)
  • Mr. Yannis Morel, Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board (Age 46)
  • Ms. Laure-Hélène Mercier, Exec. VP, CFO & Member of Exec. Board (Age 41)
  • Mr. Eric Vivier D.V.M., Ph.D., Sr. VP & Chief Scientific Officer (Age 55)

How do I buy shares of Innate Pharma?

Shares of IPHYF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Innate Pharma's stock price today?

One share of IPHYF stock can currently be purchased for approximately $6.5450.

How big of a company is Innate Pharma?

Innate Pharma has a market capitalization of $376.99 million and generates $110.96 million in revenue each year. The company earns $3.60 million in net income (profit) each year or $0.06 on an earnings per share basis. Innate Pharma employs 195 workers across the globe.

What is Innate Pharma's official website?

The official website for Innate Pharma is http://www.innate-pharma.com.

How can I contact Innate Pharma?

Innate Pharma's mailing address is 117 AVENUE DE LUMINY - BP 30191, MARSEILLE I0, 13009. The company can be reached via phone at 33-04-30-30-30-30 or via email at [email protected]


MarketBeat Community Rating for Innate Pharma (OTCMKTS IPHYF)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  97 (Vote Outperform)
Underperform Votes:  67 (Vote Underperform)
Total Votes:  164
MarketBeat's community ratings are surveys of what our community members think about Innate Pharma and other stocks. Vote "Outperform" if you believe IPHYF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPHYF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel